Phaseline

Companies › TVAX Biomedical

TVAX Biomedical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Nov 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TVI-Brain-1
Neoantigen-specific adoptive T cell therapy using attenuated autologous cancer cells and a
–Phase 2Glioblastoma Multiforme of BrainNov 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05685004TVI-Brain-1Phase 2Glioblastoma Multiforme of BrainOncologyNov 2030

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Newish Technology (Beijing) BrainChild Bio Lukas Biomedical RhoVac APS March Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.